We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Shire will pay $5.2 billion to acquire rare disease manufacturer NPS Pharma, the latest acquisition aimed at boosting the Irish drugmaker’s rare disease portfolio. Read More
Hospira has submitted a BLA for anemia drug Retacrit, a proposed biosimilar to Amgen's Epogen and Janssen's Procrit — making it the fourth company to announce submission of a biosimilar application to the FDA. Read More
The European Medicines Agency approved a record number of orphan drugs in 2014, a milestone it says is likely due to increasing early collaboration with sponsors. Read More
The FDA last week approved Daiichi Sankyo’s new blood thinner to treat certain atrial fibrillation patients based on findings the drug is safer than current treatment warfarin. Read More
The FDA approved Impax Labs’ Parkinson’s disease drug Rytary after the drugmaker agreed to not use a troubled manufacturing facility for production. Read More
European Medicines Agency advisors have recommended approval of Newron and Zambon Pharmaceuticals’ Parkinson’s disease drug Xadago in combination with levodopa or other therapies for mid- to late-stage patients experiencing motor fluctuations. Read More